Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(Combigan Ophthalmic Solution)
23 results
  • Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma. [Case Reports]
    Pediatr Dermatol 2016; 33(4):e232-4Gill K, Bayart C, … Tamburro J
  • Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α-2 adrenergic agonist, with 0.5% timolol, a nonselective β-adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Com…
  • Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribing. [Case Reports]
    BMJ Case Rep 2013; 2013Chu MB, Searcy G, Siegfried E
  • We report three patients with superficial haemangiomas treated topically with Combigan ophthalmic solution (brimonidine 0.2%-timolol 0.5%), a combination selective α-2-adrenergic agonist and non-selective β-blocker Food and Drug Administration-approved for use in glaucoma. Topical brimonidine 0.2%-timolol 0.5% therapy improved the appearance of haemangiomas in all the cases. Two patients did not …
New Search Next